| Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 127.39 mm | 127.39 mm | 127.39 mm | 127.39 mm | 127.39 mm | 127.39 mm |
| Cash burn (monthly) | 12.33 mm | (no burn) | 5.80 mm | 10.85 mm | 12.23 mm | 13.32 mm |
| Cash used (since last report) | 62.41 mm | n/a | 29.35 mm | 54.92 mm | 61.92 mm | 67.43 mm |
| Cash remaining | 64.98 mm | n/a | 98.03 mm | 72.46 mm | 65.46 mm | 59.95 mm |
| Runway (months of cash) | 5.3 | n/a | 16.9 | 6.7 | 5.4 | 4.5 |
| 13F holders | Current |
|---|---|
| Total holders | 21 |
| Opened positions | 7 |
| Closed positions | 15 |
| Increased positions | 2 |
| Reduced positions | 0 |
| 13F shares | Current |
|---|---|
| Total value | 16.14 bn |
| Total shares | 17.73 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Biotechnology Value Fund L P | 9.28 mm | $122.07 mm |
| 5am Ventures Iii | 2.01 mm | $4.01 mm |
| Canaan XII | 1.40 mm | $17.70 mm |
| Omega Fund V | 1.25 mm | $1.59 mm |
| Interwest Partners X | 903.74 k | $1.55 mm |
| Ra Capital Management | 703.08 k | $8.89 mm |
| Bain Capital Life Sciences Investors | 703.08 k | $7.56 bn |
| BCLS Fund III Investments | 703.08 k | $8.89 mm |
| Monashee Investment Management | 369.10 k | $3.97 bn |
| Vanguard | 180.54 k | $1.94 bn |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 24 Feb 25 | Karbe Frank | Common Stock | Grant | Acquire A | No | No | 0 | 57,500 | 0.00 | 57,500 |
| 24 Feb 25 | Karbe Frank | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 20.5 | 115,000 | 2.36 mm | 115,000 |
| 3 Jan 25 | Ra Capital Management | Stock Option Common Stock | Grant | Acquire A | Yes | No | 26.62 | 22,200 | 590.96 k | 22,200 |
| 3 Jan 25 | Joshua Resnick | Stock Option Common Stock | Grant | Acquire A | No | No | 26.62 | 22,200 | 590.96 k | 22,200 |
